Health2Sync's flagship app “Health2Sync 智抗糖” has already accumulated over 1.6 million users globally and captured more than 180 million health data records. Its AI-powered insulin dose adjustment software, Insultrate (易速胰), is the first digital therapeutic (DTx) approved as a Class II medical device by the TFDA (Taiwan Food and Drug Administration). Health2Sync is also collaborating with Sanofi to secure National Health Insurance (NHI) reimbursement for this digital therapeutic, aiming to become the first DTx to receive NHI reimbursement by mid-2025.
Since 2023, Health2Sync has entered Japan‘s Kenpo (Employee Health Insurance Association) market with a Value-Based Healthcare model, providing personalized and real-time employee wellness services to local governments and major corporations. The company currently collaborates with over 55 partners, including Mitsubishi Electric, Hitachi, NTT, and the governments of Osaka and Yokohama. Revenue from this initiative has doubled for two consecutive years and is projected to become Health2Sync's second-largest revenue source by 2025.
Health2Sync continues to expand its product suite to address emerging needs such as GLP-1, obesity, and chronic kidney disease (CKD) through digital interventions. By leveraging AI-driven health management, the company not only addresses the shortage of care personnel through digital innovation but also aims to establish Taiwan as a digital health innovation hub, leading the Asian digital health industry onto the global stage and transforming chronic disease care worldwide.
https://money.udn.com/money/story/5612/9147856
